BeiGene Ltd (BGNE) ADR Each Representing 13 Ord Shares

Sell:$222.64Buy:$223.05$0.64 (0.29%)

NASDAQ:1.35%
Market closed | Prices delayed by at least 15 minutes
Sell:$222.64
Buy:$223.05
Change:$0.64 (0.29%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$222.64
Buy:$223.05
Change:$0.64 (0.29%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

Key people

John Victor Oyler
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
Xiaobin Wu
President, Chief Operating Officer, General Manager - China
Xiaodong Wang
Co-Founder, Non-Executive Director
Aaron Rosenberg
Chief Financial Officer
Chan Lee
Senior Vice President, General Counsel
Giancarlo Benelli
Senior Vice President, Head of Europe
Matthew Shaulis
General Manager, North America
Lai Wang
Global Head of R&D
Ranjeev Krishana
Lead Non-Executive Independent Director
Shalini Sharp
Director
Olivier Brandicourt
Independent Non-Executive Director
Han Dugan
Non-Executive Independent Director
Michael J. Goller
Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    Cayman Islands
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US07725L1026
  • Market cap
    $25.06bn
  • Employees
    10,473
  • Shares in issue
    115.06m
  • Exchange
    Shanghai Stock Exchange
  • Index
    Shanghai SE Composite Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.